Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2021 | Latest developments in the treatment of EMD in myeloma

Artur Jurczyszyn • 30 Apr 2021
COMy 2021
Multiple Myeloma CAR-T Carfilzomib Dexamethasone Melflufen Pomalidomide
HORIZON

Artur Jurczyszyn, MD, PhD, Jagiellonian University Medical College, Kraków, Poland, outlines the latest thinking on the optimal treatment of extramedullary disease (EMD) in myeloma. Recent data from the Phase II HORIZON study of melflufen in combination with dexamethasone in patients with relapsed/refractory myeloma demonstrated promising efficacy of the combination in the EMD setting. CAR T-cell therapy is currently recommended as an effective option for the treatment of EMD. This interview took place during the 7th World Congress on Controversies in Multiple Myeloma (COMy), 2021.

More from Artur Jurczyszyn

2:20
Aims & projects of the Myeloma Treatment Foundation Centre in Poland
Artur Jurczyszyn • 26 Aug 2022
1:21
The impact of physical activity in patients with multiple myeloma
Artur Jurczyszyn • 26 Aug 2022
1:25
The importance of early treatment in MGRS & the role of the MDT
Artur Jurczyszyn • 26 Aug 2022
1:13
The importance of bone disease control in multiple myeloma
Artur Jurczyszyn • 26 Aug 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals